Geode Capital Management LLC Has $929,000 Stake in Clearside Biomedical, Inc. (NASDAQ:CLSD)

Geode Capital Management LLC increased its position in Clearside Biomedical, Inc. (NASDAQ:CLSD) by 8.8% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 731,386 shares of the company’s stock after purchasing an additional 59,089 shares during the period. Geode Capital Management LLC’s holdings in Clearside Biomedical were worth $929,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of CLSD. XTX Topco Ltd lifted its stake in shares of Clearside Biomedical by 172.2% in the second quarter. XTX Topco Ltd now owns 54,313 shares of the company’s stock valued at $71,000 after buying an additional 34,359 shares in the last quarter. Johnson & Johnson bought a new stake in shares of Clearside Biomedical during the third quarter worth about $105,000. Finally, Renaissance Technologies LLC raised its holdings in shares of Clearside Biomedical by 6.6% in the 2nd quarter. Renaissance Technologies LLC now owns 582,689 shares of the company’s stock worth $757,000 after acquiring an additional 35,900 shares during the last quarter. Institutional investors and hedge funds own 18.75% of the company’s stock.

Insider Buying and Selling

In related news, insider Ngai Hang Victor Chong acquired 36,500 shares of the company’s stock in a transaction that occurred on Friday, November 1st. The shares were acquired at an average price of $1.00 per share, with a total value of $36,500.00. Following the acquisition, the insider now owns 100,000 shares of the company’s stock, valued at approximately $100,000. This trade represents a 57.48 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 9.20% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on CLSD shares. Chardan Capital reiterated a “buy” rating and set a $6.00 price target on shares of Clearside Biomedical in a research note on Friday, November 15th. HC Wainwright restated a “buy” rating and set a $6.00 price objective on shares of Clearside Biomedical in a research note on Thursday, November 14th. StockNews.com upgraded Clearside Biomedical from a “sell” rating to a “hold” rating in a research note on Thursday, December 12th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $6.00 price target on shares of Clearside Biomedical in a research report on Wednesday, November 13th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, Clearside Biomedical currently has a consensus rating of “Moderate Buy” and a consensus price target of $5.33.

Clearside Biomedical Stock Up 0.7 %

Clearside Biomedical stock opened at $0.98 on Friday. The firm has a 50 day moving average price of $1.02 and a 200-day moving average price of $1.11. Clearside Biomedical, Inc. has a twelve month low of $0.80 and a twelve month high of $2.12. The company has a market capitalization of $74.33 million, a P/E ratio of -2.18 and a beta of 2.20.

Clearside Biomedical (NASDAQ:CLSD) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.10) EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.04. The firm had revenue of $1.04 million for the quarter, compared to analysts’ expectations of $0.25 million. During the same period in the prior year, the company earned ($0.15) EPS. Equities analysts expect that Clearside Biomedical, Inc. will post -0.48 EPS for the current fiscal year.

Clearside Biomedical Profile

Clearside Biomedical, Inc, a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD.